Brokerages Set Nurix Therapeutics, Inc. (NASDAQ:NRIX) Target Price at $29.40

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $29.40.

NRIX has been the topic of several research reports. Truist Financial started coverage on Nurix Therapeutics in a research note on Wednesday, July 31st. They set a "buy" rating and a $36.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on Nurix Therapeutics from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Monday, July 15th. Royal Bank of Canada lowered their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. UBS Group started coverage on Nurix Therapeutics in a research note on Thursday. They issued a "buy" rating and a $35.00 price objective on the stock. Finally, Oppenheimer upped their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday, September 4th.

Nurix Therapeutics Trading Up 0.7 %

NRIX traded up $0.18 on Monday, hitting $26.45. 897,792 shares of the stock traded hands, compared to its average volume of 888,351. Nurix Therapeutics has a 52 week low of $4.38 and a 52 week high of $27.60. The business has a fifty day moving average price of $24.09 and a two-hundred day moving average price of $20.01.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. As a group, research analysts predict that Nurix Therapeutics will post -2.84 earnings per share for the current year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,408 shares of the company's stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $70,443.36. Following the transaction, the insider now owns 45,150 shares of the company's stock, valued at approximately $933,250.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Gwenn Hansen sold 3,408 shares of the stock in a transaction on Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total value of $70,443.36. Following the transaction, the insider now owns 45,150 shares of the company's stock, valued at $933,250.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Houte Hans Van sold 2,490 shares of the stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the completion of the transaction, the chief financial officer now directly owns 54,479 shares in the company, valued at approximately $1,126,080.93. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,105 shares of company stock valued at $1,507,181. 9.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Nurix Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Acadian Asset Management LLC raised its stake in Nurix Therapeutics by 576.7% during the 1st quarter. Acadian Asset Management LLC now owns 160,293 shares of the company's stock worth $2,355,000 after buying an additional 136,606 shares during the period. SG Americas Securities LLC raised its stake in Nurix Therapeutics by 365.0% during the 2nd quarter. SG Americas Securities LLC now owns 103,199 shares of the company's stock worth $2,154,000 after buying an additional 81,005 shares during the period. Renaissance Technologies LLC raised its stake in Nurix Therapeutics by 80.7% during the 2nd quarter. Renaissance Technologies LLC now owns 324,000 shares of the company's stock worth $6,762,000 after buying an additional 144,700 shares during the period. TD Asset Management Inc acquired a new stake in Nurix Therapeutics during the 2nd quarter worth $593,000. Finally, Candriam S.C.A. raised its stake in Nurix Therapeutics by 30.5% during the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company's stock worth $24,297,000 after buying an additional 272,136 shares during the period.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.